Sichuan Omnis Pharmaceutical Co., Ltd. was founded in January 2013. The company focuses on the physical operation of small molecule chemical drugs and its business covers injections, lyophilized powder injection, tablets, capsules and other high-end dosage forms and APIs. The controlling shareholder of the company, Sichuan Biomedical Industry Group Co., Ltd, is a wholly-owned subsidiary of Sichuan Development Holdings Co., Ltd., which is the investment and operation main body of the biomedical industry sector in the four main responsibilities of Sichuan Development.

Sichuan Development Holdings Co., Ltd. is the Sichuan Provincial Party Committee and Provincial Government in accordance with the scale of 80 billion yuan of registered capital to form the provincial key state-owned enterprises, consolidated assets of 1.8 trillion yuan, annual revenue scale of about 400 billion yuan, for 15 consecutive years was named "AAA" credit rating. The company's business mainly focuses on eco-environmental protection, advanced materials, biomedicine, aerospace, as well as capital operation, science and technology innovation services, etc., and has business layouts in 20 provinces (autonomous regions and municipalities) across the country, as well as 45 countries and regions around the world.

The shareholder, Baiyu Pharmaceuticals, is a pharmaceutical group with a global positioning, an innovative drug as its core, and a full industrial chain integrating research, production, and sales. It is a well-known leading biomedical company in Sichuan Province. The company has a deep industrial layout in the three major sectors of traditional Chinese medicine, chemical drugs and innovative drugs. The company has eight wholly-owned subsidiaries, existing staff of more than 1,200 people, with a total asset of nearly 2 billion yuan, an average annual income of over 1 billion yuan in the past three years, and tax revenues of more than 100 million yuan, is the driving force behind the development of Chengdu Medicine, and is the most advanced and leading pharmaceutical company in China. 

On December 29, 2022, Sichuan Biomedical Industry Group Co., Ltd and Baiyu Pharmaceuticals formally signed an investment cooperation agreement to reorganize Omnis Pharmaceutical and build it into a first-class domestic pharmaceutical enterprise with product clustering, production capacity scaling and business internationalized by taking advantage of the shareholders' strengths in capital, resources, technology and talents. At present, Omnis Pharmaceutical has invested in the construction of FDF and API factories with a total area of about 280 acres, and established complete production lines and an international quality management system in accordance with the standards of EU EDQM and U.S. FDA cGMP, and has granted the GMP certificates of injection and solid preparations in China, and has passed the certification of the EU GMP and ANVISA GMP. Our products cover 6 major therapeutic areas, including thrombosis disease prevention and treatment, specialty antimicrobials, new analgesics, nervous system, digestive system and respiratory system.